LINKS
ABOUT

info@biocircuit.com

1819 Peachtree Rd NE 

Suite 350

Atlanta, Georgia 30309

© 2019 BioCircuit Technologies

OUR TECHNOLOGY

01 / FAST

I'm a paragraph. Click here to add your own text and edit me. It’s easy. Just click “Edit Text” or double click me to add your own content and make changes to the font. Feel free to drag and drop me anywhere you like on your page. 

02 / SECURE
03 / EASY

I'm a paragraph. Click here to add your own text and edit me. It’s easy. Just click “Edit Text” or double click me to add your own content and make changes to the font. Feel free to drag and drop me anywhere you like on your page. 

 

OUR TECHNOLOGY

01 / PRECISE

Nerves are fundamental to how our bodies interact with the world. While researchers and clinicians cite the need for monitoring and controlling precise neurological activity, technology to reliably enable this has not been available. BioCircuit’s team developed a technology that leverages multielectrode arrays, advanced hardware, and proprietary algorithms to develop a miniaturized solution appropriate for highly distributed single clinic, single patient use. This product opens up a new paradigm of functional nerve imaging.

02 / CONSISTENT

Decades-old traditional nerve conduction technology has several shortcomings. First, it provides a blunt readout of fairly rudimentary data. However, as important or more, it does not provide test-to-test reliability, such that clinicians cannot practically use it to track a patient’s improvement or decline over time. BioCircuit’s multielectrode array-based technology provides excellent consistency in results, not only in real time but in test-to-test reliability over time. No hand-measurements with a ruler, no manual  calculations, just statistically significant accuracy.

03 / SIMPLE

BioCircuit’s product development ethic is to make highly complex data easy to interpret, delivered in a device that is easy to operate. We drive ourselves to iterate our designs until we get “on-target, first try” with a device that can be used by operators with minimal training and little-to-no technical skill.

OUR STORY

OUR SCIENCE Taps Into Peripheral Nerve Activity at the Most Detailed, Granular Level
OUR PASSION is Producing Devices that Provide Front-line Clinicians with Precise Nerve Activity Information, Enabling them to Improve Treatment for a Number of Society’s Most Plaguing Health Conditions
Our scientific background is in cellular electrophysiology. We originated as a subsidiary within Axion Biosystems, a company that spent over 10 years combining its expertise in electrophysiology with a multi-faceted engineering team to invent research instrumentation for recreating heart beats and brain activity in culture dishes.
Alongside Axion’s product development and commercialization journey, its team conducted parallel research to determine if its core technologies could apply beyond the in vitro environment. Specifically, the goal was to provide clinicians with non-invasive access to highly-detailed nerve activity and performance, in human patients, in real time. With financial support from the NIH, Axion’s researchers successfully developed unprecedented, high-resolution access to peripheral nerve activity transcutaneously.
BioCircuit Technologies has been formed as an independent company with a focus on commercializing the technologies that will provide clinicians access to: 1) precise peripheral nerve activity in patients in real time; 2) consistent test-to-test reliability; 3) “one touch” simple-to-use products that require minimal user training.
BioCircuit’s products will provide clinicians with a practical ability to diagnose health conditions earlier, track progression of symptoms over time, and select treatments more precisely for individual patients.
 

OUR TEAM

Michelle brings 30 years of executive leadership, business development and venture capital experience, having served as a Senior Partner at McKinsey & Company, Managing Director of the GRA Venture Fund and numerous public and private Board member roles, including BioCircuit’s former parent company, Axion Biosystems. 

President & CEO

MICHELLE JARRARD

Isaac brings 15 years of industry and post-graduate experience in neurotechnology and led development of several commercially successful product lines, including Axion BioSystem's award-winning Lumos system.

Chief Technology Officer

ISAAC CLEMENTS, PhD

Co-founder of Axion BioSystems and designer of technology upon which both Axion and Biocircuit are founded, Edgar brings electronics development, signal processing, and applied mathematics expertise.

Electrical Engineer

EDGAR BROWN

A graduate of Georgia Tech's electrical engineering program, Anna is interested in applying electrophysiological principles to clinical spaces.

Project Engineer

ANNA HARRISON

As a Presidential Scholar pursuing a Master of Biomedical Engineering at Mercer University, Max is focused on research and development of medical devices with a particular emphasis on mechanical design and software development.

Research Engineer

MAXIMILIAN SONNTAG

Co-founder and CTO of Axion Biosystems, Jim brings his experience commercializing neurotechnology and building a company from startup to success.

Senior Technical Advisor

JAMES ROSS, PhD
 
 

OUR BOARD

Thomas O'Brien
Board Chair

Tom O’Brien serves as Board Chair for BioCircuit.  He has been President & CEO of Axion Biosystems since its founding over 10 years ago. Prior to that, Tom was a senior executive at Philips Medical Systems, after the sale of Intermagnetics General Corporation, where he held the role of Executive Vice President, Corporate Development and President, Invivo Medical Devices. Tom holds a Bachelor’s Degree with highest honors in Industrial Engineering from Georgia Tech and an MBA from the University of Chicago.  

James Nahirny

James was a co-founder and a Managing Director of Bain Capital Ventures, leading to dozens of investments and experience serving on the boards of numerous private and public companies. Formerly, he was a Partner at McKinsey & Company and prior to that, worked in the Mergers & Acquisitions Group of First Boston in both New York and Tokyo. James is currently the Managing Partner of Alsora Capital, investing in a number of private companies and funds, with an emphasis on healthcare. A first-generation college attendee, he graduated with a BA magna cum laude from Yale University and received an MBA with High Distinction from Harvard Business School.

Mike Masters

Mike Masters, founder of Masters Capital Management, entered the investment industry and sought to align his personal and professional values by taking a conscience-first approach to investing. This approach has been both financially and ethically rewarding as he has become an industry expert on the social role of markets and the human impact of speculation. A lifelong learner, Mike has performed extensive research in the areas of applying principles from philosophy, psychology and behavioral finance. He has authored and co-authored white papers that take a close look at the social role of markets and the real human impacts of speculation. Mike is a graduate of the University of Tennessee, where he was an All-American swimmer. He currently serves on the boards of several charitable and private organizations.

Michelle Jarrard

Michelle brings executive leadership to the BioCircuit team, drawing on years as a Board Member at Axion and 30 years of business roles including Senior Partner at McKinsey & Company and Managing Director of the GRA Venture Fund, an early stage venture capital fund focusing on companies commercializing university-originating research. She holds a Bachelor's Degree with highest honors in Industrial Engineering  from Georgia Tech and an MBA from Harvard Business School.

 

CONTACT US